Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

Fig. 3

CircNUP50 can regulate the proliferation ability, cell cycle progression, and apoptosis of OC platinum-resistant cells. A EdU experiments showed that circNUP50 knockdown reduced the proliferative activity of SKOV3/DDP and A2780/DDP cells. B circNUP50 knockdown led to cell cycle arrest at the G0/G1 phase in SKOV3/DDP and A2780/DDP cells. C circNUP50 knockdown increased the apoptosis rate in SKOV3/DDP and A2780/DDP cells. D–F Xenografts formed by SKOV3/DDP cells bearing platinum + sh-circNUP50 exhibited a significantly slower growth rate (D and E) and lower tumour weight than xenografts from control groups

Back to article page